NCT01870596 - Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Adult Acute Megakaryoblastic LeukemiaAdult Acute Monoblastic LeukemiaAdult Acute Monocytic LeukemiaAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With MaturationAdult Acute Myeloid Leukemia With Minimal DifferentiationAdult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLLAdult Acute Myeloid Leukemia Without MaturationAdult Acute Myelomonocytic LeukemiaAdult ErythroleukemiaAdult Pure Erythroid LeukemiaAlkylating Agent-Related Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid Leukemia

Interventions

DRUG

Cytarabine

Given IV

DRUG

CHK1 Inhibitor SCH 900776

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (5)

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore

21287

Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore

30342

Blood and Marrow Transplant Group of Georgia, Atlanta

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH